BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
Go back to BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults| (NASDAQ: BTAI) | Delayed: 1.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.26 | 52 Week High | $ | |||
| Open | $1.26 | 52 Week Low | $ | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.26 | EPS | $ | |||
| Volume | 8,846 | |||||
